FindTrial
Sign In

A Study of Treatment Outcomes in Hospital Acquired Superbug Infections.

Antibiotic prescription patterns and outcomes of Hospital acquired Carbapenem Resistant Acinetobacter Baumanii Infections- A prospective observational study. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/04/065399
Enrollment
200
Registered
2024-04-08
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B968- Other specified bacterial agents as the cause of diseases classified elsewhere

Interventions

None listed

Sponsors

Dr T S Shashikala
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with culture positive Carbapenem resistant Acinetobacter baumanii infections.

Exclusion criteria

Exclusion criteria: 1)Treatment is not with the intent to cure the infection (that is, palliative care is an exclusion). 2)Pregnancy or breast-feeding. 3)Polymicrobial infections 4)Patients requiring more than 2 weeks of antibiotics (Infective endocarditis, undrainable abscess, or intra-abdominal collections)

Design outcomes

Primary

MeasureTime frame
Mortality at Day 14 after diagnosis of Hospital Acquired Carbapenem Resistant Acinetobacter Baumanii InfectionsTimepoint: At baseline and at 2 weeks of diagnosis.—

Secondary

MeasureTime frame
Not ApplicableTimepoint: Not Applicable—

Countries

India

Contacts

Public ContactDr T S Shashikala

Kasturba Medical College, Manipal

drshashikalats@gmail.com9441383024

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026